Nicoya Lifesciences

Nicoya Lifesciences in its $20 million Series A extension

Client

Nicoya Lifesciences

Value

$20 million

Service

Emerging and High Growth Companies

Date Closed

December 2021

Industry

Pharmaceuticals, Biotech & Life Sciences

Lead Office

Toronto

 

On December 16, 2021, Nicoya Lifesciences announced its $20 million Series A extension led by Whitecap Venture Partners. The round included participation from strategic investor Agilent Technologies, a leading global developer of analytical instrumentation for the life sciences, as well as Export Development Canada, BDC Capital, MaRS IAF, Garage Capital, and others. The funding will fuel Nicoya’s continued development & commercialization of Alto™, an innovative surface plasmon resonance (SPR) platform that digitalizes label-free protein characterization, and expansion into new international markets. The company previously announced its $10 million Series A financing in early 2020, also led by WhiteCap, which enabled them to grow to a team of over 100 employees and launch the early adopter program for Alto.

Nicoya Lifesciences, is a Canadian life sciences tools company specializing in innovative biosensor technology for the academic, biotechnology and pharmaceutical sectors.

Osler, Hoskin & Harcourt LLP advised Nicoya Lifesciences with a team consisting of Chad Bayne, Jennifer Humphrey, and Chres Lee (Emerging & High Growth Companies).